{!{wpv-post-title}!}
ADPKD is the most common inherited kidney disorder worldwide with a prevalence between 1:400 and 1:1000. Patients eventually develop kidney failure and require dialysis. Tolvaptan is the only treatment approved in Canada. Tolvaptan reduces further growth of cysts but does not reduce the cyst burden.
Foam sclerotherapy is a novel treatment able to permanently shrink the size of cysts with minimal reported side effects. From 2014 to 2016, more than 60 patients underwent an experimental foam sclerotherapy procedure at Toronto General Hospital (TGH) with promising results!
Students:
Dr. Ioan-Andrei Iliuta
MD, MHScTR
Capstone Supervisor:
Prof. Joseph Ferenbok
Capstone Advisory Committee:
Eran
York P-C
Anna
{!{wpv-post-featured-image size=”et-pb-portfolio-image”}!}
{!{wpv-post-title}!}
Dr. Ioan-Andrei Iliuta
MD, MHScTR
ADPKD is the most common inherited kidney disorder worldwide with a prevalence between 1:400 and 1:1000. Patients eventually develop kidney failure and require dialysis. Tolvaptan is the only treatment approved in Canada. Tolvaptan reduces further growth of cysts but does not reduce the cyst burden.
Foam sclerotherapy is a novel treatment able to permanently shrink the size of cysts with minimal reported side effects. From 2014 to 2016, more than 60 patients underwent an experimental foam sclerotherapy procedure at Toronto General Hospital (TGH) with promising results!
Capstone Supervisor:
Prof. Joseph Ferenbok
Capstone Advisory Committee:
Eran
York P-C
Anna